Skip to main content
. Author manuscript; available in PMC: 2018 Sep 15.
Published in final edited form as: Biochem Pharmacol. 2017 Apr 27;140:8–15. doi: 10.1016/j.bcp.2017.04.027

Figure 2.

Figure 2

Furin nanobodies. Furin nanobodies consisting of the variable region of an antibody specific for the P-domain of furin, binds this regulatory region, inhibiting the binding of furin to physiological substrates. Note the change in shape in the catalytic site upon Nb14 binding to the P-site.